Answers are grounded in this paper and cite their sources.
Circulating tumor cells (CTCs) play a critical role in tumor metastasis, and CTCs often exhibit enhanced cancer stem cell-like properties and greater metastatic potential. Therefore, developing nanodelivery systems capable of targeting CTC-like tumor cell subpopulations, stable drug delivery, and suppression of tumor stemness is of great importance for limiting metastatic progression. In this study, a chitosan-coated hybrid lipid nanoparticle system was constructed to achieve synergistic regulation of CTC-associated metastatic processes through modulation of nanoparticle rigidity, ligand-mediated recognition, and anti-stemness activity. Specifically, N-isopropylacrylamide and N-isopropylmethacrylamide were introduced onto the chitosan backbone to synthesize a CS-graft-poly (N-isopropylacrylamide-co-N-isopropylmethacrylamide) polymer (CAM), which enhanced the structural rigidity of the nanoparticles and improved their stability during blood circulation. Meanwhile, folic acid (FA)-modified chitosan shells enabled selective recognition and stable binding to folate receptor (FR)-overexpressing CTC-like tumor cells under circulation conditions. On this basis, β-elemene (β-ELE) was loaded into CAM-coated hybrid lipid nanoparticles (CAMPs) to target cancer stemness–related signaling pathways, thereby reducing stemness-associated features of tumor cells and suppressing their metastatic potential. Through the synergistic integration of rigidity regulation, ligand-targeted recognition, and tumor stemness suppression, this nanodelivery system effectively enhances preferential interaction with CTC-like tumor cell and mitigates metastasis-associated progression.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: